Background The frequency of obesity has risen dramatically in recent years but only few
safe and effective drugs are currently available. We assessed the effect of liraglutide on …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like …

Objective To review the efficacy, safety, and clinical applicability of liraglutide for weight
management from phase III clinical trials. Methods A search of the English language …

Obesity continues to pose a major public health risk to the United States and across the
world, with an estimated one‐third of adult Americans being defined as obese. Obesity …

Importance Weight loss of 5% to 10% can improve type 2 diabetes and related
comorbidities. Few safe, effective weight-management drugs are currently available …

Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …

Background Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in
obesity. We aimed to evaluate the effects of injectable liraglutide 3· 0 mg daily on body fat …

Introduction: The prevalence of obesity is increasing worldwide and associated conditions,
particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle …

Background The combination of insulin and glucagon-like peptide-1 (GLP-1) receptor
agonist therapy improves glycaemic control, induces weight loss, and reduces insulin dose …

Background: Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss
over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the …